Search Results
Apr 13, 2026, 06:45 ET Lilly's Jaypirca (pirtobrutinib) significantly extended progression-free survival when added to a venetoclax time-limited regimen in patients with previously treated CLL/SLL
AST increased (17; 1.6), pneumonia (16; 14), bruising (16; -), potassium decreased (13; 1.6), sodium decreased (13; -), lipase increased (12; 4.4), ALT increased (11; 1.6), potassium increased (11; 0.8), alkaline phosphatase increased (11; -). Grade 4 laboratory abnormalities in >5% of patients included
More news about: Eli Lilly and Company
Apr 09, 2026, 08:41 ET Choose Health Launches Comprehensive At-Home GLP-1 Monitoring Panels for Ozempic, Wegovy and Mounjaro Users
GLP-1 Health Monitoring Panel – Basic covers 8 biomarkers including liver enzymes (ALT, AST, GGT), kidney function (creatinine, eGFR), lipase, and blood sugar markers.The
More news about: Choose Health
Apr 06, 2026, 09:00 ET Abbott recebe aprovação regulatória no Brasil de serplulimabe, novo medicamento biológico para o tratamento de câncer de pulmão de pequenas células com doença extensa, oferecendo uma nova alternativa para pacientes
content:https://www.prnewswire.com/br/comunicados-para-a-imprensa/abbott-recebe-aprovacao-regulatoria-no-brasil-de-serplulimabe-novo-medicamento-biologico-para-o-tratamento-de-cancer-de-pulmao-de-pequenas-celulas-com-doenca-extensa-oferecendo-uma-nova-alternativa-para-pacientes-302733351.htmlFONTE
More news about: Abbott
Mar 31, 2026, 09:11 ET Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development
medical management.HepatotoxicityLYMPHIR can cause hepatotoxicity. In the pooled safety population, elevated ALT occurred in 70% of patients, with Grade 3 ALT occurring in 22%; elevated AST occurred in 64% of patients, with Grade 3 AST elevation occurring in 9%. For Grade 3 events, median
More news about: Citius Oncology, Inc.
Mar 31, 2026, 08:05 ET Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology
increased alanine aminotransferase (ALT) occurred in 37% of patients, including Grade 3 or 4 in 4.8%. The median time to first onset for increased AST was 15 days (range: 5 days to 2.5 years) and increased ALT was 24 days (range: 7 days to 3.7 years). Monitor AST and ALT prior to initiating GAVRETO, every
More news about: Rigel Pharmaceuticals, Inc.
Mar 31, 2026, 05:00 ET Oracle and NetSuite Deliver New AI-Powered Solution for Restaurant Operations
leaders are under pressure to drive operational efficiencies and do more with less, while delivering an exceptional customer experience," said Alex Alt, executive vice president and general manager, Oracle Commercial Cloud Applications. "Restaurant Operations brings together deep industry-specific expertise,
More news about: Oracle
Mar 26, 2026, 16:05 ET Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
10% Grade 3/4. 85% of patients experienced increased ALT, including 13% Grade 3/4. Fatal liver events occurred in 0.6% of patients. Median time to first onset of AST or ALT elevation was 15 days (range: 3 days to 20.8 months).Increased AST or ALT each led to dose interruption in 7% of patients and
More news about: Nuvation Bio Inc.; Eisai Co., Ltd
Mar 25, 2026, 08:00 ET Alteogen Enters into a License Agreement with Biogen for Development and Commercialization of Hybrozyme™-Based Subcutaneous Biologics
therapies together for patients," said Tae-Yon Chun, CEO of Alteogen.ALT-B4ALT-B4 (berahyaluronidase alfa) is a proprietary recombinant human hyaluronidase developed using Alteogen's Hybrozyme™ platform technology. ALT-B4 enables the conversion of biologics typically administered via intravenous
More news about: Alteogen Inc.
Mar 24, 2026, 11:05 ET Anti-Aging Protein Research Takes a Step Forward with Cell Cloning
after a single intravenous infusion — a one-dose cardiovascular intervention that could reshape metabolic disease treatment.Altimmune (NASDAQ: ALT) is advancing pemvidutide, a GLP-1/glucagon dual receptor agonist for metabolic disease that targets the $65 billion metabolic syndrome
More news about: Equity Insider
Mar 24, 2026, 08:00 ET Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts
medical management.HepatotoxicityLYMPHIR can cause hepatotoxicity. In the pooled safety population, elevated ALT occurred in 70% of patients, with Grade 3 ALT occurring in 22%; elevated AST occurred in 64% of patients, with Grade 3 AST elevation occurring in 9%. For Grade 3 events, median
More news about: Citius Oncology, Inc.
Mar 19, 2026, 08:45 ET "Yeah, No" Benefit Concert Raising Funds to Support St. Anthony Village Community After Federal Immigration Operations
Perfect World, a band of St. Anthony Village teens playing 90s alt-rock bangers. Attendees will also be able to participate in a sing-along of resistance songs. All funds raised will go to
More news about: "Yeah, No" Benefit Concert
Mar 19, 2026, 08:00 ET Altesa BioSciences' Treatment for Rhinovirus Infections in People with Respiratory Conditions, Vapendavir, Selected for Oral Presentation at the International Society for Antiviral Research Conference (ICAR) 2026
metabolite inhibiting type C rhinovirusesBoth vapendavir and its major metabolite, designated as a New Chemical Entity (ALT-001), have direct activity against all three major rhinovirus species: RV-A, RV-B, and RV-CAltesa is advancing clinical development of vapendavir
More news about: Altesa Biosciences Inc.
Mar 18, 2026, 07:45 ET Fans Score with New Oracle Suite Service and Mobile Ordering Capabilities
seamless for fans and efficient for operators, yet many venues are still managing suites, ordering, and payments across disconnected systems," said Alex Alt, executive vice president and general manager, Oracle Commercial Cloud Applications. "With the latest Oracle Simphony Cloud enhancements, venues can
More news about: Oracle
Mar 17, 2026, 16:35 ET Nuvation Bio to Present Pivotal IBTROZI® (Taletrectinib) Data in TKI-Naïve and TKI-Pretreated Patients with Advanced ROS1-Positive Non-Small Cell Lung Cancer at AACR 2026
10% Grade 3/4. 85% of patients experienced increased ALT, including 13% Grade 3/4. Fatal liver events occurred in 0.6% of patients. Median time to first onset of AST or ALT elevation was 15 days (range: 3 days to 20.8 months).Increased AST or ALT each led to dose interruption in 7% of patients and
More news about: Nuvation Bio Inc.
Mar 16, 2026, 08:00 ET Celltrion announces U.S. availability of AVTOZMA® (tocilizumab-anoh) subcutaneous (SC) formulation
for early detection and management.Hepatoxicity. Monitor for hepatic injury signs. Avoid AVTOZMA if ALT/ AST >1.5x ULN (RA/GCA) or >10x ULN (COVID-19); discontinue if ALT/AST >5x ULN or symptoms of liver disease develop.Changes in Laboratory Parameters. Monitor neutrophils,
More news about: Celltrion
Mar 11, 2026, 11:45 ET REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202
up to two years post-treatment. A mean reduction in creatine kinase was observed at one year post-treatment (n=8) and supported by mean reductions in ALT (n=7), AST (n=7) and LDH (n=8).RGX-202 was well tolerated with no serious adverse events (SAEs) and no AEs of special interest (AESIs) in the
More news about: REGENXBIO Inc.
Mar 10, 2026, 08:47 ET Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers
medical management.HepatotoxicityLYMPHIR can cause hepatotoxicity. In the pooled safety population, elevated ALT occurred in 70% of patients, with Grade 3 ALT occurring in 22%; elevated AST occurred in 64% of patients, with Grade 3 AST elevation occurring in 9%. For Grade 3 events, median
More news about: Citius Oncology, Inc.
Mar 10, 2026, 08:36 ET TruLife Distribution Attends Alt Beverage Expo
included an effort to maintain a presence at top industry trade shows, and the company was excited to have some of its top brass on location for the recent Alt Beverage Expo in Florida. "We were excited to be there and to see the new innovations coming to the market in 2026," said Jimmie Carmeci, Director
More news about: TruLife Distribution
Mar 10, 2026, 07:00 ET Alt Air Teams Up with Eve Air Mobility and Skyports Infrastructure to Advance Electric Aviation in New South Wales and Queensland
the Brisbane 2032 Games."Alongside these partnerships, Alt Air will leverage existing airports and other unique aviation infrastructure assets in Sydney, including operating bases on Sydney Harbour and at Palm Beach. With Skyports, Alt Air will explore new vertiport locations to expand the network
More news about: Eve Air Mobility
Mar 10, 2026, 05:13 ET Gene Solutions, 2. Uluslararası Kalıtsal Kanserler Kongresi 2026'da Güçlü Gerçek Dünya Kanıtları ile Türkiye Pazarına Stratejik Girişini Duyurdu
Yaklaşım" başlıklı bir sunum gerçekleştirdi. Dr. Son, tekli organ taramasının sınırlamalarına değinerek, tek bir kan alımıyla 10 kanser türünü ve 75 alt tipi tespit etmek için genetik, epigenetik ve fragmentomik imzaları birleştiren; cfDNA multi-omik entegrasyonu ve makine öğrenimi temelli SPOT-MAS teknolojisine
More news about: Gene Solutions Genomics Pte Ltd
Mar 05, 2026, 15:55 ET Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line
N=448) elevated aspartate aminotransferase (AST) occurred in 47% of patients, with Grade 3 or 4 elevations in 2.9%. Elevated alanine aminotransferase (ALT) occurred in 48% of patients, with Grade 3 or 4 elevations in 3.8%. Elevated total bilirubin occurred in 10% of patients with Grade 3 or 4 elevations
More news about: Johnson & Johnson
Mar 05, 2026, 14:33 ET Huawei Ofis, Sağlık ve Eğitim için Senaryoya Özel Çözümler Sunuyor
Sinerji Ekosistemi OluşturmaHuawei'in akıllı konferans ve ofis çözümü, toplantıları planlamak için bir sesli asistan, toplantılar sırasında alt yazılarla gerçek zamanlı çeviri ve verimliliği artırmak için rol tabanlı toplantı sonrası özetler dahil olmak üzere çığır açan akıllı özellikler sunuyor.
More news about: Huawei
Mar 04, 2026, 09:15 ET Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma
medical management.HepatotoxicityLYMPHIR can cause hepatotoxicity. In the pooled safety population, elevated ALT occurred in 70% of patients, with Grade 3 ALT occurring in 22%; elevated AST occurred in 64% of patients, with Grade 3 AST elevation occurring in 9%. For Grade 3 events, median
More news about: Citius Oncology, Inc.
Mar 02, 2026, 16:05 ET Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
10% Grade 3/4. 85% of patients experienced increased ALT, including 13% Grade 3/4. Fatal liver events occurred in 0.6% of patients. Median time to first onset of AST or ALT elevation was 15 days (range: 3 days to 20.8 months).Increased AST or ALT each led to dose interruption in 7% of patients and
More news about: Nuvation Bio Inc.
Mar 02, 2026, 07:00 ET Lynk Pharmaceuticals Announces Positive Phase III Topline Data of Zemprocitinib in Moderate-to-Severe Atopic Dermatitis
reactions related to decreases in hemoglobin, neutrophils, or lymphocytes were observed and there were no safety concerns associated with elevations in ALT or AST. No dose-dependent differences in the safety profile were observed. Overall, the safety profile was consistent
More news about: Lynk Pharmaceuticals Co., Ltd.